Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Effector Therapeutics Inc (NQ: EFTR ) 0.1800 UNCHANGED Last Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Effector Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 January 09, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces Reverse Stock Split January 09, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket January 08, 2024 Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.... Via Benzinga Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session December 11, 2023 Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... Via Benzinga Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket December 11, 2023 Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... Via Benzinga eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study December 08, 2023 eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive... Via Benzinga eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients December 08, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer November 28, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting November 15, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session November 13, 2023 Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. Via Benzinga Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket November 13, 2023 StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday November 13, 2023 Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! Via InvestorPlace eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference November 06, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia October 24, 2023 Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models From eFFECTOR Therapeutics, Inc. Via GlobeNewswire 3 Promising Biotech Stocks That Will Make Early Investors Rich October 02, 2023 Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies. Via InvestorPlace eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors September 11, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences August 30, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates August 24, 2023 HC Wainwright has initiated coverage on eFFECTOR Therapeutics Inc (NASDAQ: EFTR) with a Buy rating Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023 August 24, 2023 Via Benzinga eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session August 01, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session July 28, 2023 Via Benzinga Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 28, 2023 Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. Via Benzinga eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings June 08, 2023 eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules From eFFECTOR Therapeutics, Inc. Via GlobeNewswire eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 07, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session June 06, 2023 Via Benzinga eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 31, 2023 From eFFECTOR Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Intraday Session May 31, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session May 30, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.